Reimagining Conservation Through Biotech in Pets: Where Do We Draw the Line?
In November 2025, Tom Brady told the world he had cloned his dog. Lua, a pit bull mix who died in December 2023, lives on in a genetically identical animal produced by the same biotech firm that has cloned dogs for Barbra Streisand and Paris Hilton. The internet did what the internet does: it turned on him. What interests me is less the backlash than the impulse underneath it — the very human refusal to let a particular animal end. Pet cloning is now a real, purchasable service, and it sits at the head of a stranger landscape that runs from glowing aquarium fish to a company trying to bring back the woolly mammoth. The question the original version of this article asked — where do we draw the line? — is the right one. It just deserves real examples instead of abstractions.
So let me name the actual things.
How pet cloning actually works
The process is less magical and more clinical than the word "cloning" suggests. A technician takes a small skin or blood sample, transfers the nucleus of one of those cells into a donor egg whose own genetic material has been removed, and the reconstructed egg is coaxed into becoming an embryo. A surrogate animal then carries it through a pregnancy of roughly 63 days. The result is an animal with the same DNA as the original — a delayed identical twin, not a resurrection.
What the marketing tends to skip is the attrition. Success rates are low; one welfare review put them around 16 percent of attempts, which means the surrogate mothers, the failed pregnancies, and the animals that do not survive are part of the arithmetic even when the brochure only shows the happy ending. This is the part I find hardest to look past — not because the technology is sinister, but because the cost is paid by animals who never enter the story the buyer is telling.
What it costs in 2026
If you want a number, here is one. ViaGen Pets, the dominant US provider, charges about $50,000 to clone a dog or a cat and $85,000 for a horse, paid in two installments. Fewer than ten companies offer the service worldwide; ViaGen and China's Sinogene dominate the field, and waitlists run for months.
There is a colder caveat that rarely makes the headlines. The cells have to be viable, and timing matters enormously: one owner was reportedly told that if a pet's cells were only frozen after death, the chance of the process working drops below 10 percent. The grief that drives most people to inquire usually arrives after the moment when banking the cells would have been easy. That is its own quiet cruelty.
What you get for the money
You get the genome. You do not get the dog. This is the line that matters most and the one the technology cannot cross, and Barbra Streisand — who would have every reason to defend the choice — said it most plainly of her own cloned dogs: they "may look like her late dog but are different… The soul cannot be cloned, even the personality." A clone inherits DNA. It does not inherit the rainy walk where your dog first trusted you, the specific way the light fell the afternoon you brought her home, the years that made her herself. Behavior is written by environment and chance as much as by genes. You are not getting your animal back. You are getting a new animal who happens to share her blueprint, and that is a different thing to fall in love with.
On the welfare question there is a named, authoritative position worth knowing before you spend anything. The ASPCA formally opposes pet cloning and has called for "a moratorium on the research, promotion and sale of cloned and bioengineered pets," citing the toll on the surrogate animals and the donors. You can disagree with them. You should at least know they have said it.
The fluorescent fish and the allergy-free cat
Cloning is the dramatic end of the spectrum, but the most successful genetically modified pet is one most people have already seen in a tank. GloFish — bright, fluorescent ornamental fish engineered to glow under blue or UV light — were first developed from zebrafish using a jellyfish-derived gene and went on sale in the US in 2003. They are, quietly, the most widely available genetically modified animal a person can own. The original version of this article referred to "fluorescent fish" without naming them, which is a bit like writing about a famous painting and declining to say which one.
The frontier that interests me more is the cat. Roughly one allergic reaction in the household is enough to send an animal back to a shelter, and the culprit is a single protein — Fel d 1, present in cat saliva, skin, and tears. Researchers led by Martin Chapman are now targeting that protein with CRISPR gene editing, and a study in PNAS Nexus has mapped the gene's diversity across cats — the groundwork for an actual hypoallergenic cat rather than a marketing claim. This is the rare biotech-pet application where the animal's interests and the human's might genuinely align: a cat that stays in its home instead of being surrendered. I notice I want it to work, and I notice that wanting it does not make the ethics simple.
The same company that wants to clone your dog also wants to un-extinct the mammoth
Here is the connective fact almost no one writing about this mentions. ViaGen Pets — the company cloning Tom Brady's dog — is now part of Colossal Biosciences, the de-extinction firm. The service that promises to bring back your particular dog and the mission to bring back a species share a corporate parent. The same biology, pointed at grief in one direction and at evolutionary loss in the other.
Colossal is not a fringe operation. It has raised more than $600 million and was valued at $10 billion in early 2025. And in April 2025 it made the headline that put de-extinction in everyone's feed: three gene-edited wolf pups — Romulus, Remus, and Khaleesi — presented as "dire wolves." The honest framing came from Colossal's own chief scientist, Beth Shapiro, who described them as grey wolves with about 20 genetic edits. That is the crucial nuance the "dire wolf is back" coverage flattened: de-extinction today produces functional proxies — animals engineered to carry some traits of a lost species — not resurrections. The pipeline behind them is real and dated: gene-edited "woolly mice" in March 2025, a stated goal of a mammoth calf by 2028, and an announced bluebuck project in April 2026.
Whether this is conservation or its expensive understudy is the genuine debate. A proxy animal in a fenced reserve is not a restored ecosystem, and the hundreds of millions flowing toward charismatic extinct megafauna are hundreds of millions not flowing toward the unglamorous work of keeping currently-living species from joining them. That is not an argument against the science. It is a question about where the money, and the attention, are pointed.
Questions to ask before you clone
The original version of this article gestured at "eco-ethicists" without giving a reader anything to do. So here is the practical residue — the questions I would sit with before spending $50,000 to copy an animal I loved:
- What am I actually trying to recover? If the answer is the relationship, a clone cannot return it. If the answer is the genome — a working dog's specific aptitudes, say — that is a different and more defensible reason.
- Whose welfare am I buying into? A successful clone implies surrogate mothers and failed pregnancies upstream. Am I comfortable with that arithmetic?
- Have I priced the alternative? A shelter is full of animals who need a last-chapter home now, for a fraction of the cost and none of the welfare overhead.
- Am I prepared to meet a stranger? The clone will look like your dog and behave like someone new. Can I love that animal for who it is rather than resenting it for who it isn't?
None of these have a single right answer. That is exactly why they are worth asking out loud.
The technology will keep advancing whether or not we resolve our feelings about it. GloFish are already in the tank, the CRISPR cat is in the lab, the mammoth program has a date on the calendar, and the cloned dogs are sleeping in famous houses. Drawing the line, then, is not a one-time verdict we issue from the sidelines. It is a series of small, specific decisions — what we fund, what we buy, what we are willing to ask an animal to endure for our comfort. The line moves where we put it. The least we can do is look at where we are putting it.
Frequently Asked Questions
ViaGen, the leading US provider, charges about $50,000 to clone a dog or cat and $85,000 for a horse, paid in two installments. If a pet's cells were only frozen after death, the success rate can drop below 10%.
A small skin or blood sample is taken, the cell's nucleus is transferred into a donor egg to create an embryo, and a surrogate animal carries it through a roughly 63-day pregnancy. Success rates are low, around 16% in some reviews, so multiple surrogates are often involved.
No. A clone shares its DNA but upbringing, environment and chance shape behavior. As Barbra Streisand said of her cloned dogs, 'The soul cannot be cloned, even the personality.'
De-extinction uses gene editing to recreate traits of extinct species. Colossal Biosciences' 2025 'dire wolves' were, by its own chief scientist's account, grey wolves with about 20 genetic edits, which are functional proxies rather than literal resurrections.
GloFish are genetically modified ornamental fish engineered to glow under blue or UV light, first sold in the US in 2003. They are the most widely available genetically modified pet today.
No. The ASPCA formally opposes pet cloning and has called for a moratorium on the research, promotion and sale of cloned and bioengineered pets, citing the welfare burden on surrogate and donor animals.
